The Spot sign and Tranexamic acid On Preventing ICH growth - AUStralasia Trial (STOP-AUST): Protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial

International Journal of Stroke

Volumn 9, Issue 4, 2014, Pages 519-524

  Meretoja, Atte ^a,b,c,d   Churilov, Leonid ^a,c   Campbell, Bruce C V ^b   Aviv, Richard I ^e   Yassi, Nawaf ^b   Barras, Christen ^b   Mitchell, Peter ^b   Yan, Bernard ^b   Nandurkar, Harshal ^a,f   Bladin, Christopher ^g   Wijeratne, Tissa ^a,h   Spratt, Neil J ⁱ   Jannes, Jim ^j   Sturm, Jonathan ⁱ   Rupasinghe, Jayantha ^k   Zavala, Jorge ^l   Lee, Andrew ^m   Kleinig, Timothy ⁿ   Markus, Romesh ^o   Delcourt, Candice ^p   Mahant, Neil ^q   Parsons, Mark W ⁱ   Levi, Christopher ⁱ   Anderson, Craig S ^p   Donnan, Geoffrey A ^c   Davis, Stephen M ^a,b   more..

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e UNIVERSITY OF TORONTO   (Canada)

^f ST VINCENT S HOSPITAL   (Australia)

^g BOX HILL HOSPITAL   (Australia)

^h WESTERN HOSPITAL   (Australia)

ⁱ UNIVERSITY OF NEWCASTLE   (Australia)

^j QUEEN ELIZABETH HOSPITAL   (Australia)

^k FRANKSTON HOSPITAL   (Australia)

^l NORTHERN HOSPITAL   (Australia)

^m FLINDERS UNIVERSITY   (Australia)

ⁿ ROYAL ADELAIDE HOSPITAL   (Australia)

^o ST VINCENT S HOSPITAL   (Australia)

^p ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^q WESTMEAD HOSPITAL   (Australia)

more..

Author keywords

ICH; Intracerebral hemorrhage; Spot sign; Tranexamic acid

Indexed keywords

PLACEBO; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT; CONTRAST MEDIUM;

ADULT; ARTICLE; BRAIN HEMATOMA; BRAIN HEMORRHAGE; BRAIN SIZE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTRAST MEDIUM EXTRAVASATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FOLLOW UP; GLASGOW COMA SCALE; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; STROKE PATIENT; THROMBOEMBOLISM; AGED; AUSTRALIA; BRAIN ANGIOGRAPHY; CEREBRAL HEMORRHAGE; CLINICAL TRIAL; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; FEMALE; HEMATOMA; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIFIBRINOLYTIC AGENTS; AUSTRALIA; CEREBRAL ANGIOGRAPHY; CEREBRAL HEMORRHAGE; CONTRAST MEDIA; DOUBLE-BLIND METHOD; FEMALE; HEMATOMA; HUMANS; MALE; MIDDLE AGED; TOMOGRAPHY, X-RAY COMPUTED; TRANEXAMIC ACID; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899931323     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/ijs.12132     Document Type: Article

References (46)

1. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurol 2007; 6:182-187.
2. Lees KR, Bluhmki E, von Kummer R etal. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375:1695-1703.
3. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009; 8:355-369.
4. van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 2010; 9:167-176.
5. Lozano R, Naghavi M, Foreman K etal. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2095-2128.
6. Stroke Unit Trialists' Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev 2007; (4):CD000197.
7. Donnan GA, Hankey GJ, Davis SM. Intracerebral haemorrhage: a need for more data and new research directions. Lancet Neurol 2010; 9:133-134.
8. Morgenstern LB, Hemphill JC, 3rd, Anderson C etal. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010; 41:2108-2129.
9. Steiner T, Petersson J, Al-Shahi Salman R etal. European research priorities for intracerebral haemorrhage. Cerebrovasc Dis 2011; 32:409-419.
10. Hemphill JC 3rd, Farrant M, Neill TA Jr. Prospective validation of the ICH Score for 12-month functional outcome. Neurology 2009; 73:1088-1094.
11. Meretoja A, Strbian D, Putaala J etal. SMASH-U: a proposal for etiologic classification of intracerebral hemorrhage. Stroke 2012; 43:2592-2597.
12. Brott T, Broderick J, Kothari R etal. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997; 28:1-5.
13. Davis SM, Broderick J, Hennerici M etal. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 2006; 66:1175-1181.
14. Delcourt C, Huang Y, Arima H etal. Hematoma growth and outcomes in intracerebral hemorrhage: the INTERACT1 study. Neurology 2012; 79:314-319.
15. Mayer SA, Brun NC, Begtrup K etal. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352:777-785.
16. Mayer SA, Brun NC, Begtrup K etal. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358:2127-2137.
17. Wada R, Aviv RI, Fox AJ etal. CT angiography 'spot sign' predicts hematoma expansion in acute intracerebral hemorrhage. Stroke 2007; 38:1257-1262.
18. Goldstein JN, Fazen LE, Snider R etal. Contrast extravasation on CT angiography predicts hematoma expansion in intracerebral hemorrhage. Neurology 2007; 68:889-894.
19. Demchuk AM, Dowlatshahi D, Rodriguez-Luna D etal. Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): a prospective observational study. Lancet Neurol 2012; 11:307-314.
20. Gladstone DJ, Aviv RI, Demchuk A. 'Spot Sign' Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy (SPOTLIGHT). Available at http://clinicaltrials.gov/ct2/show/NCT01359202 (accessed May 23, 2013).
21. Flaherty ML, Jauch EC. The Spot Sign for Predicting and Treating ICH Growth Study (STOP-IT). Available at http://clinicaltrials.gov/ct2/show/NCT00810888 (accessed May 23, 2013).
22. Ghinea N, Lipworth W, Kerridge I, Day R. No evidence or no alternative? Taking responsibility for off-label prescribing. Intern Med J 2012; 42:247-251.
23. Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339:245-253.
24. Shakur H, Roberts I, Bautista R etal. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376:23-32.
25. Roberts I, Shakur H, Afolabi A etal. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011; 377:1096-1101.
26. Ma H, Parsons MW, Christensen S etal. A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND). Int J Stroke 2012; 7:74-80.
27. Mehta CR, Pocock SJ. Adaptive increase in sample size when interim results are promising: a practical guide with examples. Stat Med 2011; 30:3267-3284.
28. Food and Drug Administration. Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics (DRAFT). U.S. Department of Health and Human Services, 2010. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf (accessed May 23, 2013).
29. Altman DG, Schulz KF, Moher D etal. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134:663-694.
30. Goldstein LB, Simel DL. Is this patient having a stroke? JAMA 2005; 293:2391-2402.
31. Brouwers HB, Falcone GJ, McNamara KA etal. CTA spot sign predicts hematoma expansion in patients with delayed presentation after intracerebral hemorrhage. Neurocrit Care 2012; 17:421-428.
32. Ederies A, Demchuk A, Chia T etal. Postcontrast CT extravasation is associated with hematoma expansion in CTA spot negative patients. Stroke 2009; 40:1672-1676.
33. Maramattom BV, Manno EM, Fulgham JR, Jaffe AS, Wijdicks EF. Clinical importance of cardiac troponin release and cardiac abnormalities in patients with supratentorial cerebral hemorrhages. Mayo Clin Proc 2006; 81:192-196.
34. Perel P, Al-Shahi Salman R, Constain A etal. Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study). BMJ 2011; 343:d3795.
35. van Rossum J, Wintzen AR, Endtz LJ, Schoen JH, de Jonge H. Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a double-blind controlled clinical trial. Ann Neurol 1977; 2:238-242.
36. Fodstad H, Liliequist B, Schannong M, Thulin CA. Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. Surg Neurol 1978; 10:9-15.
37. Chandra B. Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial. Ann Neurol 1978; 3:502-504.
38. Kaste M, Ramsay M. Tranexamic acid in subarachnoid hemorrhage. A double-blind study. Stroke 1979; 10:519-522.
39. Vermeulen M, Lindsay KW, Murray GD etal. Antifibrinolytic treatment in subarachnoid hemorrhage. N Engl J Med 1984; 311:432-437.
40. Roos Y. Antifibrinolytic treatment in subarachnoid hemorrhage: a randomized placebo-controlled trial. STAR Study Group. Neurology 2000; 54:77-82.
41. Roos YB, Rinkel GJ, Vermeulen M, Algra A, van Gijn J. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2003; (2):CD001245.
42. Hillman J, Fridriksson S, Nilsson O, Yu Z, Saveland H, Jakobsson KE. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. J Neurosurg 2002; 97:771-778.
43. Sprigg N. A randomised controlled trial of Tranexamic acid in Intracerebral Haemorrhage (TICH). Available at http://www.controlled-trials.com/ISRCTN50867461 (accessed May 23, 2013).
44. Sprigg N, Hogg CJ, Dineen RA, Bath PM. Tranexamic acid for acute Intracerebral Haemorrhage (TICH): baseline characteristics of enrolled patients in a randomised controlled trial. [POSTER presented at the European Stroke Conference 24 May 2012]. Cerebrovasc Dis 2012; 33:726-727.
45. Sorimachi T, Fujii Y, Morita K, Tanaka R. Rapid administration of antifibrinolytics and strict blood pressure control for intracerebral hemorrhage. Neurosurgery 2005; 57:837-844.
46. Sorimachi T, Fujii Y, Morita K, Tanaka R. Predictors of hematoma enlargement in patients with intracerebral hemorrhage treated with rapid administration of antifibrinolytic agents and strict blood pressure control. J Neurosurg 2007; 106:250-254.